Rare diseases
Investigational molecules
Locations
100 5th Avenue, 02451-8703, United States
Clinical research in complement-mediated kidney disease centers on C3 glomerulopathy and IC-MPGN, with attention to renal inflammation, proteinuria, and disease recurrence after transplantation.
These studies reflect a strong interest in renal disorders driven by dysregulation of the complement system.
Apellis Pharmaceuticals Inc. runs clinical trials in conditions such as Glomerulonephritis membranoproliferative, C3 glomerulopathy, Paroxysmal nocturnal haemoglobinuria, Focal segmental glomerulosclerosis, among others.
Clinical trials run by this sponsor – those enrolling participants first.
The Netherlands
France
Czechia
AustriaAustriaAustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
